Established in 2007, the Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both hereditary and wild-type disease, and asymptomatic carriers with TTR mutations [9]. This evidence concerns the gene TTR and Familial transthyretin-related amyloidosis.